BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 18537267)

  • 1. Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis.
    Hurshman Babbes AR; Powers ET; Kelly JW
    Biochemistry; 2008 Jul; 47(26):6969-84. PubMed ID: 18537267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation.
    Lashuel HA; Lai Z; Kelly JW
    Biochemistry; 1998 Dec; 37(51):17851-64. PubMed ID: 9922152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity.
    Hammarström P; Jiang X; Hurshman AR; Powers ET; Kelly JW
    Proc Natl Acad Sci U S A; 2002 Dec; 99 Suppl 4(Suppl 4):16427-32. PubMed ID: 12351683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cys-10 mixed disulfide modifications exacerbate transthyretin familial variant amyloidogenicity: a likely explanation for variable clinical expression of amyloidosis and the lack of pathology in C10S/V30M transgenic mice?
    Zhang Q; Kelly JW
    Biochemistry; 2005 Jun; 44(25):9079-85. PubMed ID: 15966731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissecting the structure, thermodynamic stability, and aggregation properties of the A25T transthyretin (A25T-TTR) variant involved in leptomeningeal amyloidosis: identifying protein partners that co-aggregate during A25T-TTR fibrillogenesis in cerebrospinal fluid.
    Azevedo EP; Pereira HM; Garratt RC; Kelly JW; Foguel D; Palhano FL
    Biochemistry; 2011 Dec; 50(51):11070-83. PubMed ID: 22091638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trapping the monomer of a non-amyloidogenic variant of transthyretin: exploring its possible use as a therapeutic strategy against transthyretin amyloidogenic diseases.
    Palhano FL; Leme LP; Busnardo RG; Foguel D
    J Biol Chem; 2009 Jan; 284(3):1443-53. PubMed ID: 18984591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative calorimetric study of non-amyloidogenic and amyloidogenic variants of the homotetrameric protein transthyretin.
    Shnyrov VL; Villar E; Zhadan GG; Sanchez-Ruiz JM; Quintas A; Saraiva MJ; Brito RM
    Biophys Chem; 2000 Dec; 88(1-3):61-7. PubMed ID: 11152276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentially amyloidogenic conformational intermediates populate the unfolding landscape of transthyretin: insights from molecular dynamics simulations.
    Rodrigues JR; Simões CJ; Silva CG; Brito RM
    Protein Sci; 2010 Feb; 19(2):202-19. PubMed ID: 19937650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NMR Measurements Reveal the Structural Basis of Transthyretin Destabilization by Pathogenic Mutations.
    Leach BI; Zhang X; Kelly JW; Dyson HJ; Wright PE
    Biochemistry; 2018 Jul; 57(30):4421-4430. PubMed ID: 29972637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants.
    Miller SR; Sekijima Y; Kelly JW
    Lab Invest; 2004 May; 84(5):545-52. PubMed ID: 14968122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization, but not by the kinetic mechanism characterizing T119 interallelic trans-suppression.
    Sekijima Y; Dendle MT; Wiseman RL; White JT; D'Haeze W; Kelly JW
    Amyloid; 2006 Jun; 13(2):57-66. PubMed ID: 16911959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology.
    Sekijima Y; Hammarström P; Matsumura M; Shimizu Y; Iwata M; Tokuda T; Ikeda S; Kelly JW
    Lab Invest; 2003 Mar; 83(3):409-17. PubMed ID: 12649341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydration and packing are crucial to amyloidogenesis as revealed by pressure studies on transthyretin variants that either protect or worsen amyloid disease.
    Ferrão-Gonzales AD; Palmieri L; Valory M; Silva JL; Lashuel H; Kelly JW; Foguel D
    J Mol Biol; 2003 May; 328(4):963-74. PubMed ID: 12729768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based analysis of A19D, a variant of transthyretin involved in familial amyloid cardiomyopathy.
    Ferreira P; Sant'Anna R; Varejão N; Lima C; Novis S; Barbosa RV; Caldeira CM; Rumjanek FD; Ventura S; Cruz MW; Foguel D
    PLoS One; 2013; 8(12):e82484. PubMed ID: 24358189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: implications to tetramer stability and ligand-binding.
    Trivella DB; Bleicher L; Palmieri Lde C; Wiggers HJ; Montanari CA; Kelly JW; Lima LM; Foguel D; Polikarpov I
    J Struct Biol; 2010 Jun; 170(3):522-31. PubMed ID: 20211733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of quaternary structure stability in aggregation-prone proteins under physiological conditions: the transthyretin case.
    Robinson LZ; Reixach N
    Biochemistry; 2014 Oct; 53(41):6496-510. PubMed ID: 25245430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.
    Penchala SC; Connelly S; Wang Y; Park MS; Zhao L; Baranczak A; Rappley I; Vogel H; Liedtke M; Witteles RM; Powers ET; Reixach N; Chan WK; Wilson IA; Kelly JW; Graef IA; Alhamadsheh MM
    Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9992-7. PubMed ID: 23716704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo stabilization of mutant human transthyretin in transgenic mice.
    Tagoe CE; Reixach N; Friske L; Mustra D; French D; Gallo G; Buxbaum JN
    Amyloid; 2007 Sep; 14(3):227-36. PubMed ID: 17701470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.
    Lai Z; Colón W; Kelly JW
    Biochemistry; 1996 May; 35(20):6470-82. PubMed ID: 8639594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retention of misfolded mutant transthyretin by the chaperone BiP/GRP78 mitigates amyloidogenesis.
    Sörgjerd K; Ghafouri B; Jonsson BH; Kelly JW; Blond SY; Hammarström P
    J Mol Biol; 2006 Feb; 356(2):469-82. PubMed ID: 16376939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.